Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies.
Saved in:
| Title: | Plasma Assay of Cell-Free Methylated DNA Markers of Colorectal Cancer: A Tumor-Agnostic Approach to Monitor Recurrence and Response to Anticancer Therapies. |
|---|---|
| Authors: | Zhu M; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA., Taylor WR; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA., Mahoney DW; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA., Then SS; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA., Berger CK; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA., Burger KN; Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN 55905, USA., Gonser AM; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA., Doering KA; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA., Xie H; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA., Foote PH; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA., Kaiser MW; Exact Sciences Corporation, Madison, WI 53719, USA., Allawi HT; Exact Sciences Corporation, Madison, WI 53719, USA., Hubbard JM; Allina Health Cancer Institute, Minneapolis, MN 55407, USA., Kisiel JB; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA. |
| Source: | Cancers [Cancers (Basel)] 2023 Dec 09; Vol. 15 (24). Date of Electronic Publication: 2023 Dec 09. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
